rs4607517 — GCK GCK fasting glucose GWAS variant

GCK rs4607517 — When the Pancreas Sets Its Glucose Sensor Too High

Glucokinase¹¹ Glucokinase
GCK (hexokinase-4): the enzyme that phosphorylates glucose to glucose-6-phosphate in pancreatic beta cells and hepatocytes. Often called the "glucose sensor" of the pancreas because its kinetics require relatively high glucose concentrations to activate — allowing insulin secretion to scale with blood glucose levels (GCK) occupies a unique position in metabolic biology: it is simultaneously the glucose sensor of the pancreatic beta cell and a regulator of hepatic glucose uptake. Unlike most enzymes, glucokinase is not inhibited by its own product, which means insulin secretion scales continuously with rising blood glucose — a property that keeps fasting glucose tightly regulated. Variants at this locus therefore directly alter the glucose setpoint around which the body operates every day.

rs4607517 is an intronic GWAS variant located within the GCK gene on chromosome 7 (44,196,069 on GRCh38). It does not alter the glucokinase protein sequence directly, but it tags regulatory variation that modestly shifts glucokinase expression or function in beta cells, raising the fasting glucose concentration at which insulin secretion is triggered.

The Mechanism

GCK is expressed on the minus strand of chromosome 7, and rs4607517 sits in an intronic region. As an intronic GWAS tag SNP, it likely captures regulatory variation — altered transcription factor binding, splicing efficiency, or chromatin accessibility — that modulates how much functional glucokinase the beta cell produces. The A allele at rs4607517 (plus-strand notation) is associated with slightly lower beta-cell glucokinase activity, which shifts the glucose threshold for insulin secretion upward. This results in a predictable elevation of fasting plasma glucose: approximately 0.062 mmol/L per A allele — a modest but highly reproducible effect seen across large, independent populations.

Simultaneously, beta-cell function (measured as HOMA-B, a surrogate for insulin secretory capacity) is modestly reduced²² modestly reduced
Dupuis J et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet, 2010 in A-allele carriers, consistent with a blunted glucose-sensing response.

The Evidence

The association between rs4607517 and fasting glucose is one of the most statistically robust findings in metabolic GWAS:

• The MAGIC consortium³³ MAGIC consortium
  Dupuis J et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet, 2010 meta-analysis (up to 122,744 participants) reported rs4607517 associated with fasting glucose at p=7×10⁻⁹² and with reduced HOMA-B at p=2×10⁻¹⁶ — effect allele A raises fasting glucose by ~0.062 mmol/L per copy.
• An earlier confirmation in 36,610 Europeans⁴⁴ confirmation in 36,610 Europeans
  Prokopenko I et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet, 2009 reached p=1×10⁻²⁵ for the GCK locus, establishing it alongside GCKR, G6PC2, and MTNR1B as a cornerstone glycemic locus.
• The BMI-adjusted MAGIC replication across 96,496 non-diabetic individuals⁵⁵ across 96,496 non-diabetic individuals
  Manning AK et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits. Nat Genet, 2012 reached p=8×10⁻⁵⁶, confirming the additive dose-response independent of obesity status.
• Gestational diabetes associations have been replicated in multiple Asian cohorts: Ao et al. 2021⁶⁶ Ao et al. 2021
  Ao D et al. The association of the glucokinase rs4607517 polymorphism with gestational diabetes mellitus and its interaction with sweets consumption in Chinese women. Public Health Nutr, 2021 (n=1,015) reported OR 1.35 (95% CI 1.03–1.77) for GDM, amplified to OR 1.61 among women consuming sweets at least weekly. A meta-analysis of 22 studies⁷⁷ meta-analysis of 22 studies
  Mao H et al. Meta-analysis of the relationship between common type 2 diabetes risk gene variants with gestational diabetes mellitus. PLoS One, 2012 confirmed rs4607517 among 8 SNPs with replicated GDM association across 10,336 cases and 17,445 controls.
• Long-term trajectory data from the GLACIER study⁸⁸ GLACIER study
  Renström F et al. Genetic predisposition to long-term nondiabetic deteriorations in glucose homeostasis: ten-year follow-up of the GLACIER study. Diabetes, 2011 showed that A-allele carriers at GCK had nominally accelerated worsening of fasting glucose over a decade, contributing to 64% higher risk of progressing to impaired fasting glucose compared to non-carriers in a combined multi-locus score.

The effect size (~0.062 mmol/L per allele) places this firmly in the category of common variants with individually modest but biologically informative effects. It does not in itself confer high diabetes risk, but because it acts on the core glucose-sensing machinery, the effect is invariant across environments — unlike variants that require specific dietary or lifestyle triggers to manifest.

Practical Actions

The GCK variant's mechanism points directly at meal-timing and carbohydrate load management. Because the A allele slightly raises the glucose threshold for insulin secretion, fasting glucose is elevated even before dietary exposures compound the effect. Reducing the magnitude of glucose excursions — through lower-glycemic-index carbohydrate choices, smaller meal portions, and post-meal activity — directly reduces the burden on a slightly less sensitive beta-cell glucose sensor.

For women planning pregnancy, the GDM risk is actionable: earlier screening and attentiveness to dietary sugar intake are specifically supported by the GCK evidence. A carbohydrate intake pattern avoiding frequent simple-sugar spikes is more protective than a generic "healthy diet" recommendation in this context.

Periodic fasting glucose and HbA1c monitoring is the most direct tool for AA homozygotes to catch any upward drift before it crosses diagnostic thresholds.

Interactions

GCK rs4607517 acts on the beta-cell glucose sensor; downstream effects depend on insulin sensitivity as well. Variants reducing insulin sensitivity — such as TCF7L2 rs7903146 (incretin pathway) or PPARG rs1801282 (adipogenesis/insulin signaling) — amplify the physiological consequences of a slightly higher glucokinase setpoint. GCK-related elevated fasting glucose compounds with G6PC2 rs560887, another glycemic GWAS locus acting at the glucose-6-phosphatase step in hepatic glucose output, since the two genes regulate complementary sides of fasting glucose homeostasis.